Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totalling 3,330,000 shares, an increase of 37.0% from the August 31st total of 2,430,000 shares. Based on an average trading volume of 261,900 shares, the short-interest ratio is presently 12.7 days. Approximately 15.7% of the company’s stock are sold short.
Wall Street Analysts Forecast Growth
Several research firms recently commented on PRLD. JMP Securities reissued a “market outperform” rating and set a $7.00 target price on shares of Prelude Therapeutics in a research note on Monday, September 16th. HC Wainwright upgraded shares of Prelude Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 19th. Finally, Barclays downgraded shares of Prelude Therapeutics from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a research report on Thursday, June 20th.
Get Our Latest Stock Report on Prelude Therapeutics
Institutional Investors Weigh In On Prelude Therapeutics
Prelude Therapeutics Price Performance
Shares of NASDAQ:PRLD traded down $0.09 on Friday, reaching $2.12. The company’s stock had a trading volume of 119,234 shares, compared to its average volume of 471,009. Prelude Therapeutics has a 52-week low of $1.66 and a 52-week high of $6.80. The stock has a market capitalization of $116.64 million, a P/E ratio of -1.13 and a beta of 1.52. The stock’s 50-day moving average is $4.75 and its two-hundred day moving average is $4.39.
Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.46) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.46). Equities analysts forecast that Prelude Therapeutics will post -1.85 earnings per share for the current fiscal year.
Prelude Therapeutics Company Profile
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
Featured Stories
- Five stocks we like better than Prelude Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How to Choose Top Rated Stocks
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is the NASDAQ Stock Exchange?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.